Literature DB >> 9783260

Isolation of synaptotagmin as a receptor for types A and E botulinum neurotoxin and analysis of their comparative binding using a new microtiter plate assay.

L Li1, B R Singh.   

Abstract

Clostridium botulinum neurotoxin acts on nerve endings to block acetylcholine release. Binding of the neurotoxin to a membrane receptor through its heavy chain is the first essential step in its mode of toxin action. Type E botulinum neurotoxin (BoNT/E) or type A botulinum neurotoxin (BoNT/A) receptor was purified from rat brain synaptosomes employing a neurotoxin affinity column chromatography. The protein fraction eluted from the affinity column with 0.5 M NaCl contained a 57 kDa protein as a major eluant. Immunoblotting the eluant with anti-synaptotagmin antibodies revealed that the 57 kDa protein was synaptotagmin I. Rat synaptotagmin I has been suggested as the receptor for BoNT/B (Nishiki et al., J. Biol. Chem. 269, 10498-10503, 1994) in rat brain. In this study, binding of BoNT/A and BoNT/E to synaptotagmin I was studied by a microtiter plate-based method. Binding of synaptotagmin I to BoNT/A coated on the plate was competitively reduced upon preincubation of the proteins with BoNT/E, suggesting a competitive binding of BoNT/A and BoNT/E to the receptor. Taken together, these results suggest that the same receptor protein binds to all three BoNT serotypes tested.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9783260

Source DB:  PubMed          Journal:  J Nat Toxins        ISSN: 1058-8108


  10 in total

1.  Neurotransmitter vesicle release from human model neurons (NT2) is sensitive to botulinum toxin A.

Authors:  Million Adane Tegenge; Helge Böhnel; Frank Gessler; Gerd Bicker
Journal:  Cell Mol Neurobiol       Date:  2012-02-29       Impact factor: 5.046

Review 2.  Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting.

Authors:  B R Singh
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

3.  Lipid rafts act as specialized domains for tetanus toxin binding and internalization into neurons.

Authors:  J Herreros; T Ng; G Schiavo
Journal:  Mol Biol Cell       Date:  2001-10       Impact factor: 4.138

4.  Inhibition of vesicular secretion in both neuronal and nonneuronal cells by a retargeted endopeptidase derivative of Clostridium botulinum neurotoxin type A.

Authors:  J A Chaddock; J R Purkiss; L M Friis; J D Broadbridge; M J Duggan; S J Fooks; C C Shone; C P Quinn; K A Foster
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

Review 5.  Botulinum toxins--cause of botulism and systemic diseases?

Authors:  H Böhnel; F Gessler
Journal:  Vet Res Commun       Date:  2005-05       Impact factor: 2.459

Review 6.  Entering neurons: botulinum toxins and synaptic vesicle recycling.

Authors:  Claudia Verderio; Ornella Rossetto; Carlotta Grumelli; Carolina Frassoni; Cesare Montecucco; Michela Matteoli
Journal:  EMBO Rep       Date:  2006-10       Impact factor: 8.807

7.  Comparative membrane channel size and activity of botulinum neurotoxins A and E.

Authors:  Sweta Parikh; Bal Ram Singh
Journal:  Protein J       Date:  2007-01       Impact factor: 4.000

8.  Crystal structure of the cytosolic C2A-C2B domains of synaptotagmin III. Implications for Ca(+2)-independent snare complex interaction.

Authors:  R B Sutton; J A Ernst; A T Brunger
Journal:  J Cell Biol       Date:  1999-11-01       Impact factor: 10.539

9.  In Silico Conformational Features of Botulinum Toxins A1 and E1 According to Intraluminal Acidification.

Authors:  Grazia Cottone; Letizia Chiodo; Luca Maragliano; Michel-Robert Popoff; Christine Rasetti-Escargueil; Emmanuel Lemichez; Thérèse E Malliavin
Journal:  Toxins (Basel)       Date:  2022-09-17       Impact factor: 5.075

10.  Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells.

Authors:  Min Dong; David A Richards; Michael C Goodnough; William H Tepp; Eric A Johnson; Edwin R Chapman
Journal:  J Cell Biol       Date:  2003-09-22       Impact factor: 10.539

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.